NCT05597202View on ClinicalTrials.gov

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

PHASE4UnknownINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

April 30, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

Semaglutide, 2.0 mg/mL

Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.

Trial Locations (1)

1105AZ

RECRUITING

AMC, Amsterdam

Sponsors

Collaborators (1)

Dutch Heart Foundation

All Listed Sponsors

collaborator

Dutch Heart Foundation

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER